MedTrace Logo

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

NCT00651144 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-02-17

No results posted yet for this study

Summary

The purpose of this study is to obtain data of the coadministration of ezetimibe and rosuvastatin to support the concomitant use of these two drugs in patients requiring additional cholesterol-lowering management. Treatment is administered for 14 days.

Conditions

Interventions

DRUG

Ezetimibe + Rosuvastatin

oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days

DRUG

Rosuvastatin

oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days

DRUG

Placebo

oral tablets; two ezetimibe placebo once daily for 14 days

DRUG

Ezetimibe

oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2003-05-31
Completion
2003-05-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651144 on ClinicalTrials.gov